Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by 99942Apophison Feb 05, 2021 5:35pm
386 Views
Post# 32489235

Liver Cancer Research

Liver Cancer Research Don't know if this has been posted.

A bis-indazolic ruthenium(II) complex: Reactivity and biological studies on cancer cells


Highlights

 

Metal complexes exhibited anticancer activity against different tumor cell lines.

Suitable induction and selective cytotoxicity to cancer cell lines.

DNA fragmentation is a biological effect of the metal complex in HepG2 cells.

Cell death promoted by the bis-indazolic metal complex caused by apoptosis in HepG2 cells.

 

Abstract

Ru(II)-based complexes have been widely investigated as potential anticancer agents, leading cell death of tumor mass. In this work, a metal complex, cis-[RuII(Hind)2(bpy)2](PF6)2 (Hind = indazole and bpy = 2,2′-bipyridine), was synthesized and characterized by elemental analysis, spectroscopy and electrochemistry methods, validating its formulation. This complex can act as a Brnsted-Lowry acid with pKa close to physiological pH. Photosubstitution reaction was noticed upon blue light irradiation with release of indazol molecules in acetonitrile, a behavior also noticed, indicating its photosensitivity. This metal complex was screened in vitro against distinct human cancer cell lines. Hepatocellular carcinoma cells (HepG2) were the most sensitive, with the half maximal inhibitory concentration (IC50) at 7.2 µmol L−1. Further biological studies showed DNA fragmentation induced by this compound, which resulted in cell cycle arrest in S phase and HepG2 cell death by apoptosis. Moreover, there was no significant cytotoxicity against healthy human pulmonary fibroblast cells (MRC-5), and therefore the compound exhibited a high selectivity index, indeed a better in vitro anticancer profile than some structurally related compounds (e.g. NAMI-A and KP1039). Our results indicate exciting potential pharmacological applications of this metal complex in liver cancer treatment, which might be supported by further studies.

Graphical abstract

A new KP1339 analogue ruthenium complex, cis-[Ru(Hind)2(bpy)2](PF6)2, showed expressive cytotoxicity against liver cancer cells, HepG2, causing DNA fragmentation, interrupting the cell cycle in phase S and resulting in cell death by apoptosis.

 

 

Abbreviations

B16-F10
murine melanoma
bpy
2,2′-bipyridine
CDDP
cisplatin
COSY
homonuclear correlation spectroscopy
DFT
density functional theory
DMF
dimethylformamide
DMSO
dimethyl sulfoxide
DMSOd6
deutered dimethyl sulfoxide
DNA
deoxyribonucleic acid
Egap
electronic gap
Fc
ferrocene
FOR000
cis-[RuCl2(bpy)2]
FOR002
cis-[RuCl(indazole)(bpy)2]PF6
FOR0D2
cis-[Ru(indazole)2(bpy)2](PF6)2
HCT116
human colon carcinoma
HepG2
hepatocellular carcinoma cells
Him
imidazole
Hind
indazole
HOMO
highest occupied molecular orbital
IC50
inhibitory concentration 50%
IL
intraligand
INCA
National Cancer Institute of Brazil
KP1019
(H2ind)[trans-RuCl4(Hind)2]
KP1339
Na[trans-RuCl4(Hind)2]
LED
light emitting diode
LLCT
ligand-to-ligand charge transfer
LUMO
lowest unoccupied molecular orbital
MLCT
metal-to-ligand charge transfer
MRC-5
pulmonary fibroblast cells
NAMI-A
(H2im)[trans-RuCl4(S-DMSO)(Him)]
PTBA
tetrabutylammonium perchlorate
SI
selectivity index
TACE
transarterial chemoembolization
TD-DFT
time-dependent density functional theory
TLD 1443
[Ru(4,4′-dimethyl-2,2′-bipyridine)2(2-(2′,2″:5″,2′′′-terthiophene)-imidazo[4,5-f][1,10]phenanthroline)]2+
λmax
band of electronic absorption spectroscopy

<< Previous
Bullboard Posts
Next >>